The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These adva
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.
MD Anderson, Rigel Team Up to Advance Olutasidenib in Cancer Fight miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Rigel Pharma (RIGL) and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML and Other Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.